2026-04-29T22:45:41Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/183422024-09-27T12:08:09Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927

00925njm 22002777a 4500 dc Lozano, Rebeca author Lorente, David author Aragon, Isabel M author Nombela, Paz author Mateo, Joaquim author Reid, Alison H M author Cendón, Ylenia author Bianchini, Diletta author Llacer, Casilda author Sandhu, Shahneen K author Sharp, Adam author Rescigno, Pasquale author Garcés, Teresa author Pacheco, Maria I author Flohr, Penelope author Massard, Christophe author López-Casas, Pedro P author Castro, Elena author de Bono, Johann S author Olmos, David author 2021-05-12 Circulating tumor cell (CTC) enumeration and changes following treatment have been demonstrated to be superior to PSA response in determining mCRPC outcome in patients receiving AR signaling inhibitors but not taxanes. We carried out a pooled analysis of two prospective studies in mCRPC patients treated with docetaxel. CTCs were measured at baseline and 3-6 weeks post treatment initiation. Cox regression models were constructed to compare 6-month radiographical progression-free survival (rPFS), CTCs and PSA changes predicting outcome. Among the subjects, 80 and 52 patients had evaluable baseline and post-treatment CTC counts, respectively. A significant association of higher baseline CTC count with worse overall survival (OS), PFS and time to PSA progression (TTPP) was observed. While CTC response at 3-6 weeks (CTC conversion (from ≥5 to 10.3390/cancers13102334 2072-6694 Cancers http://hdl.handle.net/10668/17888 34066080 http://hdl.handle.net/20.500.12105/18342 PSA biomarkers circulating tumor cells docetaxel metastatic castration-resistant prostate cancer Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients.